Literature DB >> 2642446

Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins.

J S Redfern1, M Feldman.   

Abstract

Active immunization of rabbits with the principal, endogenous prostaglandins in the gastrointestinal mucosa induces gastrointestinal mucosal ulceration. Development of ulceration in prostaglandin-immunized rabbits appears to be a direct consequence of production of specific prostaglandin antibodies, as prostaglandin antibodies per se induce gastric ulceration within 9 days when administered intravenously to unimmunized rabbits. These studies suggest that endogenous prostaglandin E2, F2 alpha, D2, and I2 in the gastrointestinal tract play an important role in preventing mucosal ulceration. The mechanism of ulcer formation is not completely understood, but most evidence points toward prostaglandin antibodies inducing mucosal ulceration by binding to endogenous prostaglandins within the mucosa and thereby negating their mucosal protective effects. Gastric acid hypersecretion and complement fixation by prostaglandin-antiprostaglandin complexes are not likely involved in the development of mucosal ulceration in this model. Use of antibodies to interfere with prostaglandin action may be an alternative approach to investigate (a) the importance of endogenous prostaglandins in mediating mucosal protective mechanisms and (b) the role of prostaglandins in acute and chronic erosive/ulcerative diseases of the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642446     DOI: 10.1016/s0016-5085(89)80055-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Nonsteroidal anti-inflammatory drugs and ulcers.

Authors:  A H Soll
Journal:  West J Med       Date:  1992-10

2.  Impaired response of gastric vessels to prostaglandin E2 in rats with persistent obstructive jaundice.

Authors:  Y Nagahata; Y Azumi; H Moritomo; N Numata; N Kawakita; M Yano; H Onoyama; M Yamamoto
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

Review 3.  A reader's guide to the evaluation of causation.

Authors:  T Podrebarac; P Tugwell; P C Hébert
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

Review 4.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

5.  Reduction of non-steroidal anti-inflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide.

Authors:  J M Scheiman; A Tillner; T Pohl; A Oldenburg; S Angermüller; E Görlach; G Engel; K H Usadel; K Kusterer
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

Review 6.  Improving the gastrointestinal safety of NSAIDs: the development of misoprostol--from hypothesis to clinical practice.

Authors:  F E Silverstein
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

7.  NSAIDs: the emperor's new dogma?

Authors:  I Bjarnason; K Takeuchi; R Simpson
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

Review 8.  Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?

Authors:  Helenie Kefalakes; Theodoros J Stylianides; George Amanakis; George Kolios
Journal:  Eur J Clin Pharmacol       Date:  2009-08-27       Impact factor: 2.953

9.  Roles of Ca2+ and protein kinase C in regulation of prostaglandin E2 release by cultured rabbit gastric epithelial cells.

Authors:  S Ota; Y Hata; A Terano; K Yoshiura; H Hiraishi; T Kawabe; H Mutoh; S Shiina; T Sugimoto
Journal:  Dig Dis Sci       Date:  1993-08       Impact factor: 3.199

Review 10.  Cyclooxygenase-2 inhibitors: promise or peril?

Authors:  Laurel J Mengle-Gaw; Benjamin D Schwartz
Journal:  Mediators Inflamm       Date:  2002-10       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.